Oxurion NV — Director's Dealing 2024

Jan 12, 2024

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC

Leuven, BELGIUM – January 12, 2024 – 8:00 AM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation¹ it has received a transparency notification as follows:

Oxurion received a transparency notification on January 8, 2024, from Atlas Special Opportunities, LLC indicating that as of January 3, 2024, it held 104,273,585 shares of the then outstanding 3,489,458,972 shares, and therefore crossed below the threshold (3%) by virtue of the sale of voting securities. See Annex 1.

About Oxurion

Oxurion (Euronext Brussels: OXUR) is engaged in developing next-generation standard of care ophthalmic therapies for the treatment of retinal disease. Oxurion is based in Leuven, Belgium. More information is available at www.oxurion.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forwardlooking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

For further information please contact:

Oxurion NV	US
Pascal Ghoson	Conway Communications
Chief Executive Officer	Mary T. Conway
Pascal.ghoson@oxurion.com	mtconway@conwaycommsir.com
__

1. Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings.

ANNEX 1

FSMA FINANCIAL SERVICES AND MARKETS AUTHORITY	Transparency notification Form TR-1 BE PART I
1) Status of the notification
Final
2) Issuer
Name OXURION Identification number 0881-620-924
3) Reason for the notification
Acquisition or disposal of voting securities or voting rights Downward crossing of the lowest threshold
4) Notification by
A person that notifies alone	$+$
5) Persons subject to the notification requirement
Name	Address (for legal entities)
6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)
Name	Address (for legal entities)
Atlas Special Opportunities LLC	2500 Westchester Avenue, Suite 401, Purchase, NY 10577
Please continue entering the information in part II concerning the Part II persons referred to in Sections 5 and 6
7) Date on which the threshold is crossed
03/01/2024 (DD/MM/YYYY)
8) Threshold that is crossed (in %)
$\overline{3}$
If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10

9) Denominator

3,489,458,972 Please enter the denominator before filling in the data

10) Notified details

A) Voting rights	Previous notification	After the transaction
	# of voting rights	# of voting rights		% of voting rights
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Atlas Special Opportunities LLC	241.545.893	104.273.585		2.99%	0.00%
TOTAL		104,273,585		2.99%

Start with "groups" of holders. Add subtotals with $\Sigma$ , and then finish with the persons who are "alone".
For groups, start with the ultimate controlling natural person or legal entity.
The totals, subtotals and % will b

$\pm$

Envelope ID: F5E0ECD7-DECC-47B6-8387-8DA993574BEB

B) Equivalent financial instruments After the transaction # of voting rights
that may be
acquired if the
instrument is
exercised Holders of equivalent
financial instruments Exercise period or
date Type of financial instrument Expiration date % of voting rights Settlement $\ddot{}$ TOTAL

The totals will be updated once you have clicked on

TOTAL (A & B)			# of voting rights % of voting rights
	CALCULATE	104,273,585	2.99%

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

Atlas Special Opportunities LLC is not a controlled entity.

12) In case of proxy voting for only one GM

			(DD/MM/YYYY
Hold	will cease to hold / will hold again	voting rights as of

13) Additional information

On 2 January 2024, Atlas Special Opportunities LLC sold 115,464,423 shares in Oxurion NV, as a result of which its shareholding decreased to 126,081,470 shares (= 3.61%, with denominator = 3,489,458,972).
On 3 January 2024, Atlas Special Opportunities LLC sold 21,807,885 shares in Oxurion NV, as a result of which its shareholding decreased to 104,273,585 shares (= 2.99%, with denominator = 3,489,458,972).

	Done at New York
On		04/01/2023 (DD/MM/YYYY)
	Name & capacity Patrick Vance, proxyholder

Signature Patrick Vance